- Home
- Insights
- Value Based Healthcare
- Global Outcomes Benchmarking
Global Outcomes Benchmarking
GLOBE and the ICON-ICHOM Partnership
The Global Outcomes Benchmarking (GLOBE) program launched by the International Consortium for Health Outcomes Measurement (ICHOM) aims to provide risk-adjusted, international benchmarks on health outcomes by medical condition. Rather than focusing on clinical indicators, ICHOM shifts the focus to outcomes that patients care about, including functional improvements and the capacity to live productive lives. Standard Sets provide a common language and approach to measuring targeted outcomes – ICHOM currently has Standard Sets that cover over 54% of the global disease burden.
Through its strategic relationship with ICON, ICHOM is creating a secure central platform where outcomes data is compiled from participating provider organisations around the world. This will enable provider organisations to compare the health outcomes of their patients to those of their peers. Leveraging the powerful analytics capabilities of ICONIK and the statistical and risk modelling of ICON’s statistics department, both ICHOM and provider organisations will be able to make informed recommendations from evidence-based data on the best treatment options that will provide the best outcomes for their patients. The collaborative nature of this global project will enable the discovery of new approaches that cost less and are more effective, leading to improvements in value-based healthcare.
ICON and ICHOM unveiled the world’s first global patient outcomes benchmarking platform at the 2017 ICHOM annual conference. The platform enables the collection, storage, aggregation, analysis and visualisation of health outcomes data. This work was done in close collaboration with the provider organizations who have full ownership of the data and the clinical leaders and patients in the working groups who defined the datasets in the first place.
This secure platform will provide decision support tools and insights to participating healthcare organizations for optimising and improving patient outcomes, using ICHOM developed Standard Sets.
Advancing value-based healthcare
Value-based health care is care that delivers the best possible outcomes to patients for the lowest possible cost. Harvard economist Michael Porter, a leader in the value-based healthcare movement, recognises that “the central driver of value improvement is outcomes measurement.” ICON and ICHOM, are measuring and reporting on outcomes that matter to patients and are creating a secure platform to assess and compare outcomes from healthcare providers around the world.
Together we are advancing value-based care by enabling the healthcare and clinical research industry to be more consistent, transparent, and patient-centric. In a landscape where payers and providers are increasingly shifting to new payment and delivery models, the opportunity exists for sponsors to optimise value across the product lifecycle through the use of benchmarked patient outcomes data and other forms of Real World Intelligence.
Perspectives:
-
physician
Compare outcomes to that of their peers. Identify best practices, change behaviours, gain feedback. -
Patient
Doctors are making evidence-based treatment decisions. -
Payer
Reimburse for the right treatments at the right time. Steer patients to the best providers.
ICON interest in benchmarking across the industry
ICON has an established history in supporting benchmarking to drive more efficient and standardized clinical research processes in clinical development, saving costs and reducing timeframes. In addition to partnering with ICHOM, ICON is a member of the Metrics Champion Consortium (MCC), an industry association dedicated to using global benchmarking metrics to improve clinical trials, and Transcelerate, a global collaborative initiative across the biopharmaceutical research and development community that is dedicated to designing new solutions that drive efficiency in the delivery of new medicines.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel